Nasal Antihistamine Spray May Prevent COVID Infection – Trial

Nasal Antihistamine Spray May Prevent COVID Infection – New clinical results from German researchers suggest a familiar nasal spray could lower the chance of getting infected with covid. A well-run randomized study tested azelastine versus placebo in healthy adults, most of whom had vaccines.

The study had 450 participants who used the spray three times daily for 56 days. Tests were done twice weekly and by PCR when a rapid test was positive. The results showed fewer infections and a longer time to infection with azelastine.

The side effects were mostly mild — a bitter taste, occasional nosebleeds, and tiredness. For people weighing how to layer protection, these findings are worth a close look, while remembering vaccines remain central to reducing serious illness and overall risk.

Key Takeaways – Nasal Antihistamine Spray May Prevent COVID Infection

• Azelastine nasal spray was tested in a high-quality randomized trial of 450 adults.
• Infections and symptomatic cases were lower with the active spray versus placebo.
• Participants used the spray three times daily and had regular testing.
• Side effects were generally mild and short-lived.
• Vaccines still play the main role; the spray may offer an added layer during high transmission.

What the new trial reveals right now

Published findings in JAMA Internal Medicine give clear numbers showing how azelastine performed versus placebo. The study found COVID-19 infections in 2.2% of the azelastine group compared with 6.7% in the placebo group.

Symptomatic COVID-19 infection was 1.8% versus 6.3%. Overall respiratory infections occurred in 9.3% with azelastine and 22% with placebo. Most participants were vaccinated and tested twice weekly with rapid antigen tests; PCRs confirmed positives.

The results also showed a longer average time to infection: 31 days with azelastine versus 19 days in the placebo arm. That delay could matter for reducing onward spread during periods of active virus circulation.

• Headline effect: roughly a 70% relative reduction in COVID infections in this sample.
• Broader impact: fewer respiratory infections overall suggest possible activity beyond SARS‑CoV‑2.
• Testing rigor: twice-weekly RATs plus PCR adds confidence that infections were captured reliably.

covid infection may prevented common nasal antihistamine spray trial: key design, dosing, and results

Saarland University enrolled 450 healthy adults and randomized them to azelastine 0.1% or an identical placebo. The double‑blind, placebo‑controlled design kept arms balanced so outcomes could be compared fairly.

Who was studied

Participants averaged about 33 years old. Most were vaccinated adults and followed the same testing schedule. Safety checks monitored both arms throughout the follow‑up.

Dosing and testing cadence

Enrollees used the nasal spray three times daily for 56 days. Self-tests (rapid antigen) were done twice weekly and PCRs confirmed positives. After exposure or symptoms, dosing could increase to five times daily for three days to mimic real‑world use.

Headline numbers

The azelastine group had 2.2% COVID‑19 infection versus the 6.7 placebo group. Symptomatic cases were 1.8% versus 6.3%. Mean time to infection was 31 days for azelastine and 19 days for placebo. Overall respiratory infections were 9.3% vs 22%.

Measure	Azelastine group	Placebo group
Participants enrolled	~225	~225
COVID‑19 infection	2.2%	6.7%
Symptomatic infection	1.8%	6.3%
Mean time to infection (days)	31	19
Any respiratory infection	9.3%	22%

How an antihistamine nasal spray could help block respiratory viruses

A nasal spray that alters the nose’s environment could lower the chance a virus gains a foothold. Researchers suggest multiple ways azelastine might act in the nasal lining to cut initial infection.

Possible mechanisms

• Binding in the nasal mucosa: azelastine may stick to viral particles and reduce their mobility across the nose lining.
• ACE2 interaction: the spray could interfere with the receptor many viruses use to attach, limiting early entry.
• Enzyme inhibition: lab data hint the compound may block an enzyme the virus needs to replicate, lowering viral load at the entry site.

Expert perspective

JAMA Internal coverage and comments from internal medicine specialists temper excitement with caution. Dr. Robert Bals called azelastine a potential OTC prophylactic, not a replacement for vaccines.

Dr. William Messer noted the three-times-daily regimen affects adherence and said masks can be easier for some people. Dr. Peter Chin-Hong said evidence is promising but not yet strong enough for broad use; he sees the spray as an additive layer during higher risk periods.

Safety, access, and limits: what U.S. readers should know

U.S. readers should know how availability and side effects shape real-world use of azelastine nasal products. In the United States, Astepro Allergy (azelastine 0.15%) is sold over the counter, giving people easy access to a counter nasal spray option.

Other markets differ: Australia offers Azep 0.1% OTC, while the UK commonly requires a prescription for brands such as Rhinolast or Azelair.

The German study reported mostly mild harms: a bitter taste, occasional nosebleeds, and tiredness. Serious events were rare and not linked to the spray.

Practical takeaways

• Availability: a counter nasal spray like Astepro gives adults a convenient option without a prescription.
• Side effects: expect bitter taste, occasional nosebleeds, and tiredness; these matched participants’ experience in the study.
• Limits: the study was single-site with mostly young, vaccinated adults, so results may not generalize to all groups.
• Context: pair any spray with updated vaccines and other measures to lower your risk covid-19 and respiratory infections.

Conclusion

Conclusion

The JAMA Internal Medicine report from Saarland University shows promising findings: the azelastine group had lower infection rates than the placebo group, including the 6.7 placebo group figure cited in the paper. Participants used an azelastine nasal regimen three times for 56 days with twice-weekly testing and PCR confirmation.

Researchers and internal medicine experts call for larger, multicenter studies to confirm these results. For people in the U.S., a counter azelastine nasal spray could be a practical add-on during high-risk periods, but vaccines remain the primary protection for older or high-risk groups. The study suggests fewer respiratory infections and delayed infection timing, yet broader work is needed to define real-world benefit and adherence impact.

FAQ

What did the Saarland University study test?

The randomized, double-blind, placebo-controlled study tested an azelastine nasal spray used three times daily for 56 days. Participants performed twice-weekly rapid tests to track infections. The trial compared infection rates between the spray group and a placebo group.

What were the main results reported in JAMA Internal Medicine?

The study found lower COVID-19 infection rates in the azelastine group (2.2%) versus the placebo group (6.7%). Researchers noted the difference as a promising signal but emphasized the need for larger studies to confirm the effect across variants and settings.

How might an antihistamine nasal spray reduce respiratory virus risk?

Lab and clinical data suggest azelastine can bind in the nasal mucosa, interfere with viral entry pathways such as ACE2 interactions, and potentially inhibit enzymes viruses use to infect cells. These mechanisms could reduce the chance of upper respiratory infection when applied early.

Should people in the U.S. start using azelastine spray to prevent COVID-19 now?

Not yet as a replacement for vaccines or proven prevention tools. The spray is available over the counter in some regions for allergy relief, but its protective role against COVID-19 requires more evidence and regulatory guidance before widespread recommendation.

Are there side effects to be aware of?

Common side effects include a bitter taste, mild nosebleeds, and occasional tiredness. Most adverse events in the study were mild. Anyone with chronic nasal conditions or concerns should consult a clinician before regular use.

Did the study compare the spray to masks or vaccines?

The trial did not replace masks or vaccines. JAMA Internal Medicine commentary framed the spray as a potential complementary tool, not a substitute for vaccination, masking in high-risk settings, or other public-health measures.

How often was the spray used in the study?

Participants self-administered the spray three times a day for 56 days. Testing occurred twice weekly to monitor infections and capture symptom onset promptly.

Who funded and conducted the research?

Saarland University led the trial and reported results in JAMA Internal Medicine. The published paper includes details on funding and potential conflicts of interest; readers should review the article for full transparency.

Can azelastine spray protect against other respiratory viruses?

Early laboratory work and prior studies suggest antihistamines like azelastine may affect several respiratory viruses by acting in the nose, but clinical evidence is limited. Larger trials are needed to confirm protection beyond SARS-CoV-2.

Where can I find reliable information about this study?

Read the JAMA Internal Medicine article for primary data, consult U.S. health agencies for guidance, and ask your healthcare provider about how this spray might fit into your personal prevention plan.